Mymd Pharmaceuticals (NASDAQ:QCLS) Shares Up 5.4% – What’s Next?

Mymd Pharmaceuticals, Inc. (NASDAQ:QCLS) shares shot up 5.4% during mid-day trading on Monday . The stock traded as high as $2.81 and last traded at $2.75. 75,025 shares were traded during mid-day trading, a decline of 61% from the average daily volume of 190,927 shares. The stock had previously closed at $2.61.

Analyst Ratings Changes

Several analysts have commented on QCLS shares. Wall Street Zen raised shares of Mymd Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, May 23rd. Weiss Ratings assumed coverage on shares of Mymd Pharmaceuticals in a report on Wednesday, May 13th. They set a “sell (e+)” rating on the stock. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Mymd Pharmaceuticals has a consensus rating of “Sell”.

Mymd Pharmaceuticals Stock Performance

The stock has a market cap of $11.93 million, a price-to-earnings ratio of -0.14 and a beta of 2.16. The company has a fifty day moving average of $3.65.

Mymd Pharmaceuticals (NASDAQ:QCLS) last posted its earnings results on Friday, May 15th. The company reported ($0.19) earnings per share (EPS) for the quarter.

About Mymd Pharmaceuticals

MyMD Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for immune-related and other serious diseases. The company has worked on product candidates designed to address conditions involving inflammation, immune system dysfunction, and age-related disease processes.

The company’s pipeline has included drug development programs in areas such as autoimmune and inflammatory disorders, with an emphasis on advancing compounds through preclinical and clinical evaluation.